SLC20A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7128814	1.00	1/20
SCHEMBL7631719	0.86	1/20
SCHEMBL7126685	0.83	1/20
SCHEMBL7120286	0.74	1/20
SCHEMBL12201483	0.72	1/20
SCHEMBL6380677	0.71	1/20
SCHEMBL7208743	0.70	1/20
SCHEMBL5110940	0.66	1/20
SCHEMBL6862230	0.66	1/20
SCHEMBL5115424	0.66	1/20
SCHEMBL7128725	0.66	1/20
SCHEMBL7530790	0.65	1/20
SCHEMBL7578393	0.64	1/20
SCHEMBL7572438	0.63	1/20
SCHEMBL27179805	0.63	1/20
SCHEMBL30927042	0.63	1/20
SCHEMBL5120085	0.63	1/20
SCHEMBL23200355	0.63	1/20
SCHEMBL30926890	0.63	1/20
SCHEMBL7209341	0.62	1/20

Clinical trials — most relevant to SLC20A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	PHASE4	COMPLETED
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH	PHASE3	COMPLETED
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease	PHASE2	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Healthy Combine Study	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia	nan	COMPLETED
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study	nan	COMPLETED
Sodium Transport: Genetics and Hypertension	nan	COMPLETED
Calcitonin for Treating X-linked Hypophosphatemia	nan	COMPLETED
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Oxalate and Citrate	nan	RECRUITING
Studying Phosphorus Metabolism	nan	COMPLETED
Blood Pressure Control in Juveniles - Longitudinal Study	nan	COMPLETED
Epidemiology of Gout in French Polynesia	nan	COMPLETED
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC20A2 binder may also engage these)

Protein	Name	Similarity
Q28E01	—	1.000	Q28E01 →
A1A4I1	—	1.000	A1A4I1 →
Q5XHF9	—	1.000	Q5XHF9 →
Q9ES44	—	1.000	Q9ES44 →
Q95L97	—	1.000	Q95L97 →
Q80UP8	—	1.000	Q80UP8 →
Q6PFM1	—	1.000	Q6PFM1 →
Q5BL44	—	1.000	Q5BL44 →
Q9JJP0	—	1.000	Q9JJP0 →
Q61609	—	1.000	Q61609 →
Q63488	—	1.000	Q63488 →
O97596	—	1.000	O97596 →
Q5R9L5	—	1.000	Q5R9L5 →
SLC20A1	Sodium-dependent phosphate transporter 1	1.000	landscape →
Q6PB26	—	0.999	Q6PB26 →
Q6NV12	—	0.997	Q6NV12 →
Q68F35	—	0.994	Q68F35 →
Q9JIS8	—	0.986	Q9JIS8 →
Q27960	—	0.986	Q27960 →
P15710	—	0.985	P15710 →
Q5REV9	—	0.983	Q5REV9 →
Q9DBP0	—	0.983	Q9DBP0 →
Q924N4	—	0.983	Q924N4 →
Q9UHW9	—	0.982	Q9UHW9 →
A0JNI9	—	0.982	A0JNI9 →
Q5DTL9	—	0.982	Q5DTL9 →
B0JZG0	—	0.981	B0JZG0 →
Q5Z413	—	0.981	Q5Z413 →
Q0DWA9	—	0.981	Q0DWA9 →
S4R2P9	—	0.981	S4R2P9 →